our Class III directors will serve until the third annual meeting of stockholders
Results for “Buchan III”
Search across the indexed text of every released document.
Names that match “Buchan III”
358 documents found
of which Mr. Garcia III is the sole beneficiary
of which Mr. Garcia III is a beneficiary together with his children. While Ernest Garcia II is the investment
875 shares of Class A common stock owned directly by Ernest Garcia III
the trust is irrevocable and Mr. Garcia II is not a beneficiary. Mr. Garcia III is the sole
no estan sujetos a su fiscalizacion; (iii) Que por tratarse de valores no inscritos
and that these will be attractive investment opportunities for NLV-III. One factor that
Table of Contents ANNEX 100K MILESTONE GIFT On September 10, 2018, we announced a commitment by our chief executive officer, Ermest Garcia III, to contribute 165 shares of Class A common stock to us from his personal shareholdings for every one of our then-existing employees u...
etc). 18 debra and children ? current and future involvement . notifications etc. . new dynasty trust ? 19. tax plan and dislosures gaming. foreign apollo and phaidon related . 20. investments rationalize incl trading accouints .21. bank loans . rates ? ? terms etc. consolidate....
IV. OPPORTUNITY IN THE HEALTHCARE SECTOR The Fund Managers believe a number of macro market factors have aligned to create attractive and lasting conditions for NLV-III’s targeted investment strategy in healthcare technology. Each of these market factors individually would have...
From: Kathy Ruemmier Sent: 9/19/2014 7:46:28 PM To: jeffrey E. [[email protected]] Subject: Re: Fwd: Importance: — High Correct. One time, maybe. Twice, no way. On Sep 19, 2014 3:45 PM, "jeffrey E." <[email protected]> wrote: of course not , he wouldnt have been so st...
Source Entry: H\Macintosh HD\root\Users\jee\Library\Messages\Archive\2018-10-23\III on 2018-10-23 at 07.16.16.ichat Service: iMessage Start Time: 10/23/18 04:16:16 AM (561986176) End Time: 10/23/18 06:06:30 PM (562035990) Last Message ID: 22577 Chat Room: Participants: jee, Prese...
Journal of Medicine editorial (November 2013), where Janet Woodcock, MD, the FDA’s Director of the Center for Drug Evaluation and Research and other senior FDA staff members as co-authors, discussed the FDA’s new breakthrough therapy designation that can be granted to expedite th...
From: Kathy Rue ler Sent: 9/19/2014 9:12:49 PM To: jeffrey E. [[email protected]] Subject: Re: Fwd: Importance: — High I think I should do it. On Sep 19, 2014 4:12 PM, "jeffrey E." <[email protected]> wrote: free now On Fri, Sep 19, 2014 at 3:46 PM, Kathy Ruemmler i:...
Flags: 1085445 Is Read: No Is Invitation: No GUID: 4390079F-7123-4AD6-9924-0EC2F8EB09C3 Message: Cannot do 5 Sender: iii Time: 04/20/17 11:58:21 AM (514407501) Flags: 1060865 Is Read: Yes Is Invitation: No GUID: EOC7EBD9-30A5-4802-8E8A-D83BAE932ED0 Message: Can do 4? Se...